Molecular Imaging and Biology最新文献

筛选
英文 中文
Metabolic Shift Mirrors GBM Immunity to Anti-PD-L1 Immunotherapy: A Deuterium MRS Study. 代谢转移反映了抗pd - l1免疫治疗对GBM的免疫:一项氘MRS研究。
IF 2.5 4区 医学
Molecular Imaging and Biology Pub Date : 2025-10-03 DOI: 10.1007/s11307-025-02037-w
Joel R Garbow, Xia Ge, Tanner M Johanns, John A Engelbach, Keith M Rich, Joseph J H Ackerman
{"title":"Metabolic Shift Mirrors GBM Immunity to Anti-PD-L1 Immunotherapy: A Deuterium MRS Study.","authors":"Joel R Garbow, Xia Ge, Tanner M Johanns, John A Engelbach, Keith M Rich, Joseph J H Ackerman","doi":"10.1007/s11307-025-02037-w","DOIUrl":"https://doi.org/10.1007/s11307-025-02037-w","url":null,"abstract":"<p><strong>Background/objectives: </strong>Immune checkpoint blockade (ICB) therapy has been ineffective in glioblastoma (GBM) that recurs following standard-of-care resection and chemoradiation of the primary tumor. Herein, we investigate whether the delayed effect of intracranial radiation alters the tumor lesion metabolic profile.</p><p><strong>Methods: </strong>Naïve (non-irradiated) GL261 tumor cells were implanted into the brains of C57BL/6 mice. Brains of one cohort were hemispherically irradiated six weeks prior to implantation, ultimately resulting in ICB refractory GBM. Brains of the control cohort were not irradiated. Following subcutaneous infusion of [6,6-<sup>2</sup>H<sub>2</sub>] glucose (Glc), single voxel deuterium metabolic imaging (DMI) monitored Glc uptake and the production of semi-heavy water (HOD), <sup>2</sup>H<sub>2</sub>-lactate (Lac) and the 50/50 mix of [<sup>2</sup>H<sub>2</sub>-glutamate + <sup>2</sup>H<sub>2</sub>-glutamine] (Glx).</p><p><strong>Results: </strong>GL261 tumors growing in previously irradiated brain showed reduced Warburg effect (aerobic glycolysis; glucose → lactate) and greater TCA cycle activity (respiration, oxidative phosphorylation) relative to tumors growing in non-irradiated brain as evidenced by cohort differences in the ratios Glx/Lac (p < 0.01), Glx/Glc (p < 0.02), and Lac/Glc (p < 0.01).</p><p><strong>Conclusions: </strong>A metabolic program skewed toward oxidative phosphorylation and away from glycolysis has been associated with immune dysfunction. This study documents such a skewed metabolic state in ICB refractory GL261 GBM growing in irradiated brain (tumors were not irradiated) compared to control brain.</p>","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145225507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Peptide Receptor Radionuclide Therapy with Lu-177-DOTATATE and Monitoring with Somatostatin Receptor PET/CT in Patients with Advanced Differentiated Thyroid Carcinoma. 晚期分化型甲状腺癌患者肽受体核素治疗与生长抑素受体PET/CT监测。
IF 2.5 4区 医学
Molecular Imaging and Biology Pub Date : 2025-09-29 DOI: 10.1007/s11307-025-02053-w
Sophie Carina Kunte, Vera U Wenter, Adrien Holzgreve, Gabriel T Sheikh, Liam Widjaja, Franz Josef Gildehaus, Simon Lindner, Ralf Schirrmacher, Christine Spitzweg, Christoph J Auernhammer, Rudolf A Werner, Mathias J Zacherl
{"title":"Peptide Receptor Radionuclide Therapy with Lu-177-DOTATATE and Monitoring with Somatostatin Receptor PET/CT in Patients with Advanced Differentiated Thyroid Carcinoma.","authors":"Sophie Carina Kunte, Vera U Wenter, Adrien Holzgreve, Gabriel T Sheikh, Liam Widjaja, Franz Josef Gildehaus, Simon Lindner, Ralf Schirrmacher, Christine Spitzweg, Christoph J Auernhammer, Rudolf A Werner, Mathias J Zacherl","doi":"10.1007/s11307-025-02053-w","DOIUrl":"https://doi.org/10.1007/s11307-025-02053-w","url":null,"abstract":"<p><strong>Purpose: </strong>Peptide receptor radionuclide therapy (PRRT) with Lu-177-DOTATATE is an established treatment option for neuroendocrine tumors (NETs) and has been extended to other somatostatin receptor (SSTR)-expressing tumors. We aimed to determine its efficacy and safety profile in patients with advanced radioiodine-refractory differentiated thyroid carcinoma (DTC).</p><p><strong>Methods: </strong>Seven radioiodine-refractory DTC patients undergoing at least two cycles of PRRT were included. Patients were subdivided into continuous treatment (defined as sequential application of PRRT; 5/7 (71.4%)) vs. discontinuous treatment (with at least one-year PRRT-free interval; 2/7 (28.6%)). Baseline SSTR PET was analyzed to determine patients' eligibility for PRRT. Response was assessed by tumor control as defined by stable (± 30.0%) or decreasing (≥ 30.0%) total tumor volume (PET-derived TTV), thyroglobulin (Tg) and RECIST 1.1 criteria.</p><p><strong>Results: </strong>SSTR PET showed discernible high uptake (maximum standardized uptake values, 10.4 ± 8.6) in metastases, in particular in the skeleton. Continuous PRRT showed variable tumor control (stable disease / response; TTV: 3/5 (60.0%); Tg: 2/5 (40.0%); RECIST 1.1: 3/5 (60.0%)). All patients undergoing discontinuous PRRT exhibited concordant stable disease upon first follow-up and renewed tumor control upon reinitiating PRRT (RECIST 1.1; decreasing TTV and Tg levels). No Common Terminology Criteria for Adverse Events (CTCAE) Grade 3-5 events occured in both groups.</p><p><strong>Conclusion: </strong>In advanced radioiodine-refractory DTC, PRRT may be beneficial even after treatment interruptions, without major side effects. Given the small cohort and retrospective design, further prospective studies are needed to optimize PRRT strategies in DTC, in particular in a rechallenge scenario.</p>","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145192149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gold Nanoparticles in Atherosclerosis: A Dual Approach to Diagnosis and Therapy. 金纳米颗粒在动脉粥样硬化中的应用:诊断和治疗的双重途径。
IF 2.5 4区 医学
Molecular Imaging and Biology Pub Date : 2025-09-22 DOI: 10.1007/s11307-025-02050-z
Elaheh Mirhadi, Prashant Kesharwani, Vasily N Sukhorukov, Amirhossein Sahebkar
{"title":"Gold Nanoparticles in Atherosclerosis: A Dual Approach to Diagnosis and Therapy.","authors":"Elaheh Mirhadi, Prashant Kesharwani, Vasily N Sukhorukov, Amirhossein Sahebkar","doi":"10.1007/s11307-025-02050-z","DOIUrl":"https://doi.org/10.1007/s11307-025-02050-z","url":null,"abstract":"<p><p>Atherosclerosis (AS) is a chronic condition defined by the accumulation of plaque fundamentally resulting from the deposition of low-density lipoprotein and fibrous compounds within injured arteries. Current treatments for atherosclerosis are effective, but the complex and not fully understood underlying mechanisms limit their effectiveness. Moreover, early detection of AS continues to be a real challenge. Innovative therapeutic approaches, such as the application of nanomedicines and theragnostic, are increasingly attracting the interest of researchers globally. Gold nanoparticles (AuNPs) exhibit significant potential as theragnostic agents in the context of atherosclerosis, providing both diagnostic and therapeutic functionalities. This review will discuss current strategies utilizing AuNPs and explore potential future advancements involving theragnostic AuNPs that may aid in addressing AS.</p>","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145125113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preclinical Evaluation of an Anti-EphA2 Minibody-Based ImmunoPET Agent as a Diagnostic Tool For Cancer. 基于抗epha2小体的免疫pet试剂作为癌症诊断工具的临床前评估
IF 2.5 4区 医学
Molecular Imaging and Biology Pub Date : 2025-09-19 DOI: 10.1007/s11307-025-02048-7
Peggy A Birikorang, H E G Wedaarachchi, Jordan A Smith, Gary Kohanbash, W Barry Edwards
{"title":"Preclinical Evaluation of an Anti-EphA2 Minibody-Based ImmunoPET Agent as a Diagnostic Tool For Cancer.","authors":"Peggy A Birikorang, H E G Wedaarachchi, Jordan A Smith, Gary Kohanbash, W Barry Edwards","doi":"10.1007/s11307-025-02048-7","DOIUrl":"https://doi.org/10.1007/s11307-025-02048-7","url":null,"abstract":"<p><strong>Purpose: </strong>In this study, we report the development and characterization of a copper-64 (<sup>64</sup>Cu) radiolabeled anti-EphA2 minibody (Mb) for pre-treatment characterization of antigen expression via Positron Emission Tomography (PET). Minibodies, ≈85 kDa molecular weight antibody fragments, are advantageous as targeting molecules due to accelerated serum clearance which enables imaging at earlier time points relative to the parent IgG. As EphA2, a tyrosine kinase receptor, is overexpressed in various cancer types with minimal expression in normal tissue, rapid quantification of EphA2 expression could be beneficial for patient stratification.</p><p><strong>Procedures: </strong>Recombinantly produced anti-EphA2-Mb was evaluated for purity, stability, affinity, and in vivo target localization. Following bifunctional chelator conjugation, radiolabeling with <sup>64</sup>Cu and evaluating purity, stability and immunoreactivity of resultant radioimmunoconjugate, [<sup>64</sup>Cu]Cu-NOTA-anti-EphA2-Mb, 11.1 MBq (300 μCi) and 0.2 MBq (5 μCi) doses were administered to HT1080-fibrosarcoma-bearing nude mice for in-vivo PET imaging and ex-vivo biodistribution analyses respectively at 4 and 24 h post-injection (p.i.). Antigen-specificity was assessed via a blocked control group which received the dose co-administered with non-radiolabeled anti-EphA2-Mb.</p><p><strong>Results: </strong>Anti-EphA2-Mb produced via recombinant protein expression was pure, stable and had high binding affinity to human EphA2 antigen (K<sub>D</sub> = 0.63 ± 0.24 nM). When labeled with <sup>64</sup>Cu via NOTA, [<sup>64</sup>Cu]Cu-NOTA-anti-EphA2-Mb had high purity, in-vitro stability in PBS and mouse serum up to 24 h, and high immunoreactivity. On administering to tumor-bearing mice, [<sup>64</sup>Cu]Cu-NOTA-anti-EphA2-Mb exhibited rapid tumor targeting with 25.53±2.92%ID/g at 4 h, and 22.13±7.68%ID/g at 24 h p.i. Competitive inhibition reduced tumor uptake (11.24±0.88%D/g, 24 h p.i., p = 0.0286). There was minimal uptake of the radiotracer in non-target tissues, except kidney and liver, and fast clearance from the blood, with high tumor to blood ratios. Tumor SUV<sub>mean</sub> values obtained from region of interest (ROI) Quantification of the PET images were 1.13±0.03 and 1.08±0.06 at 4 and 24 h respectively.</p><p><strong>Conclusion: </strong>Our findings demonstrate that anti-EphA2-Mb is an excellent targeting molecule, and [<sup>64</sup>Cu]Cu-NOTA-anti-EphA2-Mb is a promising immunoPET agent with potential for use for other theranostic applications.</p>","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145092148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Today's Research, Tomorrow's Practice - White Paper from the Translation of New Therapy (TNT) Radiotheranostics Kick-off Pre-meeting of the Annual World Molecular Imaging Conference 2024. 今天的研究,明天的实践-新疗法(TNT)放射治疗翻译白皮书启动2024年世界分子成像年会会前会议。
IF 2.5 4区 医学
Molecular Imaging and Biology Pub Date : 2025-09-19 DOI: 10.1007/s11307-025-02054-9
Simone Krebs, Lisa Baird, Giacomo Pirovano, Aiko Yamaguchi, Ryan P Coll, Jason T Lee, Laurence S Carroll, Martin G Pomper, H Charles Manning
{"title":"Today's Research, Tomorrow's Practice - White Paper from the Translation of New Therapy (TNT) Radiotheranostics Kick-off Pre-meeting of the Annual World Molecular Imaging Conference 2024.","authors":"Simone Krebs, Lisa Baird, Giacomo Pirovano, Aiko Yamaguchi, Ryan P Coll, Jason T Lee, Laurence S Carroll, Martin G Pomper, H Charles Manning","doi":"10.1007/s11307-025-02054-9","DOIUrl":"10.1007/s11307-025-02054-9","url":null,"abstract":"<p><p>Theranostics, a concept combining \"therapy\" and \"diagnostics\", is poised to enter an exponential growth phase. By using specific diagnostic markers to guide the selection and application of targeted treatments directed at those markers, this approach aims to improve effectiveness and reduce unnecessary interventions. While several agents have been approved by the FDA recently, multiple additional theranostics are being developed, studied in clinical trials and expected to enter clinical practice in short order. As part of the \"Translation of New Therapy (TNT) Interest Group's Radiotheranostics Kick-off\" pre-meeting of the annual World Molecular Imaging Conference (WMIC) 2024 over 350 attendees with 10% leaders from industry, 60% senior and junior investigators in academia and 30% trainees discussed the key challenges and opportunities in implementing a theranostic research program in academia, which are addressed in this white paper. Overarching themes included funding, regulatory hurdles, and workforce training. Panel recommendations included leveraging existing expertise and patient populations, securing revenue streams, exploring alternative funding sources, and developing a multifaceted approach to promote training, education and public awareness, including fostering academic-industry partnerships. By shedding light on the gap between research and real-world program implementation, this white paper and forthcoming pre-meetings at WMIC aim to define a practical framework for building successful programs based on insights from recent research.</p>","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145086510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of New NanoAlbumin-based Radiotracers: Preclinical Evaluation Of [68Ga]Ga-DOTA-nanoHSA Conjugates for Lymphatic Imaging Applications. 新型纳米白蛋白示踪剂的开发:[68Ga] ga - dota -纳米hsa偶联物淋巴成像应用的临床前评估。
IF 2.5 4区 医学
Molecular Imaging and Biology Pub Date : 2025-09-15 DOI: 10.1007/s11307-025-02049-6
Vijayaraj Kuniyil Kulangara, Aida Mary Abreu Diaz, Sara M Elkashef, Miriam Ruiz Pena, Mariia Kiseleva, Samila Leon Chaviano, Yat Hei Leung, Indranil Nandi
{"title":"Development of New NanoAlbumin-based Radiotracers: Preclinical Evaluation Of [<sup>68</sup>Ga]Ga-DOTA-nanoHSA Conjugates for Lymphatic Imaging Applications.","authors":"Vijayaraj Kuniyil Kulangara, Aida Mary Abreu Diaz, Sara M Elkashef, Miriam Ruiz Pena, Mariia Kiseleva, Samila Leon Chaviano, Yat Hei Leung, Indranil Nandi","doi":"10.1007/s11307-025-02049-6","DOIUrl":"https://doi.org/10.1007/s11307-025-02049-6","url":null,"abstract":"<p><strong>Purpose: </strong>Sentinel lymph node (SLN) mapping is a critical procedure in the staging and treatment of cancers, such as breast cancer and melanoma. Current radiocolloids used in SLN localization, like [<sup>99m</sup>Tc]Tc-Sulfur Colloid, face limitations in imaging resolution and specificity. This study aims to evaluate the biodistribution of [<sup>68</sup>Ga]Ga-DOTA-nanoHSA, a novel nanoparticle-based radiotracer, for SLN mapping using PET/CT imaging in both healthy and tumor-bearing murine models and compare results with [<sup>99m</sup>Tc]Tc-Sulfur Colloid as the current gold standard for lymph node staging in breast cancer. Additionally, the maximum tolerated dose and potential systemic toxicity of the carrier were assessed in humanized mice.</p><p><strong>Methods: </strong>Nanoalbumin radiotracers were prepared by thermal denaturation of human serum albumin (HSA), followed by conjugation with 2,2',2″,2″'-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetic acid (DOTA) and labeling with gallium-68. The stability of [<sup>68</sup>Ga]Ga-DOTA-nanoHSA was evaluated in the tracer formulations and in mouse serum. The novel radiotracers were administered subcutaneously and intratumorally in healthy and tumor-bearing mice, respectively, to evaluate SLN uptake via PET/CT imaging. Biodistribution was assessed in major organs, and the tracers' ability to accurately localize SLNs was compared to an existing standard. Toxicity was evaluated in humanized mice, where body weight, clinical scoring, and blood chemistry were monitored over a 14-days period. Mice received escalating doses of DOTA-nanoHSA to determine the maximum tolerated dose.</p><p><strong>Results: </strong>[<sup>68</sup>Ga]Ga-DOTA-nanoHSA tracers (30 nm and 70 nm) were reliably produced with high radiochemical purity (RCP > 90%). The stability of [<sup>68</sup>Ga]Ga-DOTA-nanoHSA (30 nm) in the final formulations at pH 3.5 and 7.0 and in mouse serum was confirmed up to 4-6 h. [<sup>68</sup>Ga]Ga-DOTA-nanoHSA (30 nm) demonstrated effective SLN localization in both healthy and tumor-bearing mice, with high uptake in SLNs and minimal off-target accumulation in non-lymphatic organs. DOTA-nanoHSA was well-tolerated in humanized mice, with no significant changes in body weight, clinical scores, or blood chemistry parameters, even at higher doses. No dose-dependent toxicity was observed.</p><p><strong>Conclusion: </strong>[<sup>68</sup>Ga]Ga-DOTA-nanoHSA (30 nm) demonstrated significant potential as a novel imaging agent for SLN mapping. Its favorable toxicity profile, combined with its effectiveness in SLN localization, suggests it could be a valuable alternative for SLN biopsy in clinical practice. Further studies are warranted to confirm these findings in human trials.</p>","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145070063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of Age and BMI on Histamine H3 Receptor Availability in Healthy Humans. 年龄和BMI对健康人组胺H3受体可用性的影响
IF 2.5 4区 医学
Molecular Imaging and Biology Pub Date : 2025-09-12 DOI: 10.1007/s11307-025-02047-8
Yanghong Yang, Waleed Ibrahim, Paul Gravel, Brian Pittman, Jocelyn Hoye, Ryan Cool, Faranak Ebrahimian Sadabad, Ming-Qiang Zheng, Christopher Pittenger, Jean-Dominique Gallezot, Richard E Carson, Henry Huang, Rajiv Radhakrishnan, David Matuskey
{"title":"Effects of Age and BMI on Histamine H3 Receptor Availability in Healthy Humans.","authors":"Yanghong Yang, Waleed Ibrahim, Paul Gravel, Brian Pittman, Jocelyn Hoye, Ryan Cool, Faranak Ebrahimian Sadabad, Ming-Qiang Zheng, Christopher Pittenger, Jean-Dominique Gallezot, Richard E Carson, Henry Huang, Rajiv Radhakrishnan, David Matuskey","doi":"10.1007/s11307-025-02047-8","DOIUrl":"https://doi.org/10.1007/s11307-025-02047-8","url":null,"abstract":"<p><strong>Purpose: </strong>To assess alterations in H3R availability with age and body mass index (BMI) in healthy humans using in vivo [<sup>11</sup>C]GSK189254 positron emission tomography (PET) imaging.</p><p><strong>Procedure: </strong>Twenty-four healthy individuals (2 females, 22 males; age range 20-47 years) were scanned with [<sup>11</sup>C]GSK189254 with High-Resolution Research Tomograph (HRRT) or HR plus scanner. Regional V<sub>T</sub> (volume of distribution) values were computed using the two-tissue compartment model. The correlation between V<sub>T</sub> and age, BMI were examined, adjusting for relevant potential confounding effects of age or gender and injected mass.</p><p><strong>Results: </strong>H3R availability (V<sub>T</sub>) was correlated with age but not BMI. V<sub>T</sub> displayed a negative correlation with age in the anterior cingulate cortex (r = -0.61, p = 0.004), frontal cortex (r = -0.50, p = 0.020), olfactory cortex (r = -0.50, p = 0.022), parietal cortex (r = -0.58, p = 0.006), cerebellum cortex (r = -0.53, p = 0.013), insula (r = -0.48, p = 0.027), putamen (r = -0.46, p = 0.034), thalamus (r = -0.45, p = 0.038), and hippocampus (r = 0.45, p = 0.039).</p><p><strong>Conclusion: </strong>This in vivo H3R study found a significant age-related decline in most cortical and subcortical regions.</p>","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145040870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PSMA-1-DOTA Potentially for Effective Targeted Radioligand Therapy of Prostate Cancer. PSMA-1-DOTA可能是前列腺癌有效的靶向放射治疗。
IF 2.5 4区 医学
Molecular Imaging and Biology Pub Date : 2025-09-02 DOI: 10.1007/s11307-025-02046-9
Xinning Wang, Olga Sergeeva, Maxim Sergeev, Lifang Zhang, Zoey Lockwood, Patrick Wojtylak, Riley Sangster, David Reichert, Marc Berridge, Wolfgang Weber, Zhenghong Lee, James P Basilion
{"title":"PSMA-1-DOTA Potentially for Effective Targeted Radioligand Therapy of Prostate Cancer.","authors":"Xinning Wang, Olga Sergeeva, Maxim Sergeev, Lifang Zhang, Zoey Lockwood, Patrick Wojtylak, Riley Sangster, David Reichert, Marc Berridge, Wolfgang Weber, Zhenghong Lee, James P Basilion","doi":"10.1007/s11307-025-02046-9","DOIUrl":"10.1007/s11307-025-02046-9","url":null,"abstract":"<p><strong>Purpose: </strong>While PSMA-targeted radioligand therapy (RLT) has shown remarkable efficacy for treating end-stage prostate cancer, the α-emitting RLT often results in severe salivary gland toxicity, limiting its use. Various strategies to mitigate this side effect have been attempted with limited success. Accordingly, this study introduced a new PSMA-targeting ligand with more favorable binding characteristics than the existing ligands.</p><p><strong>Procedures: </strong>The binding affinity of PSMA-1-DOTA to PSMA was compared with that of PSMA-11 and PSMA I&T. Comparison of uptake in the salivary glands, kidneys and PC3pip tumor cells in the xenograft mouse models between [<sup>68</sup> Ga]Ga-PSMA-1-DOTA, [<sup>68</sup> Ga]Ga-PSMA-11 and [<sup>68</sup> Ga]Ga-PSMA I&T was conducted with microPET/CT within the same week. The same mouse models were treated with [<sup>177</sup>Lu]Lu-PSMA-1-DOTA or [<sup>177</sup>Lu]Lu-PSMA-617. A compassionate use PET imaging study on a patient with metastatic castration-resistant prostate cancer was performed using [<sup>68</sup> Ga]Ga-PSMA-1-DOTA.</p><p><strong>Results: </strong>The binding affinity of PSMA-1-DOTA to PSMA was found to be approximately four times greater than other PSMA-targeted ligands. Imaging with microPET/CT revealed significantly lower kidney, uptake and little salivary and lacrimal gland uptake with [<sup>68</sup> Ga]Ga-PSMA-1-DOTA compared to other PSMA-radioligands. Preclinical efficacy studies demonstrated that [<sup>177</sup>Lu]Lu-PSMA-1-DOTA inhibited tumor growth comparable to that with [<sup>177</sup>Lu]Lu-PSMA-617, suggesting its potential to enhance the therapeutic window of targeted RLT by avoiding damage to the salivary glands. The compassionate use PET imaging confirmed the reduced salivary gland uptake of [<sup>68</sup> Ga]Ga-PSMA-1-DOTA in the patient, indicating its potential utility as a targeting agent for RLT with α- or β-emitting radionuclides in patients with PSMA-positive prostate cancer.</p><p><strong>Conclusion: </strong>PSMA-1-DOTA shows reduced uptake in salivary glands while effectively targeting PSMA-expressing tumors, thus potentially avoiding the side effects of xerostomia, and possibly moving PSMA-targeted RLT to a more frontline therapy for prostate cancer rather than the current use as a last resort.</p>","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144961563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tailoring Image Contrast for Cellular Magnetic Resonance Imaging using Gadolinium Chelates and Superparamagnetic Iron Oxide Particles. 使用钆螯合物和超顺磁性氧化铁颗粒定制细胞磁共振成像图像对比度。
IF 2.5 4区 医学
Molecular Imaging and Biology Pub Date : 2025-08-21 DOI: 10.1007/s11307-025-02044-x
Young Beom Kim
{"title":"Tailoring Image Contrast for Cellular Magnetic Resonance Imaging using Gadolinium Chelates and Superparamagnetic Iron Oxide Particles.","authors":"Young Beom Kim","doi":"10.1007/s11307-025-02044-x","DOIUrl":"https://doi.org/10.1007/s11307-025-02044-x","url":null,"abstract":"<p><p>To investigate magnetic relaxation properties of the tailored contrast using paramagnetic gadolinium (Gd) chelates and superparamagnetic iron oxide particles (SPIOs) for cellular magnetic resonance imaging. The study included three different exposed environments with two different characteristic contrast agents which used gadodiamide (Omniscan; Gd-DTPA-BMA) and ferumoxide (Feridex; SPIO) in C6 brain cancer cells. Based on the minimal mutual interaction between these two agents in vitro, we examined the possibility of using mixture of cells that are separately labeled with two contrast agents or using concurrently labeled cells with different concentrations of the two contrast agents. In order to characterize the MR relaxation properties, aqueous solutions containing various concentrations of the two contrast agents were prepared as well as Ficoll solution suspensions containing labeled cells by different labeling schemes and subsequently investigated R<sub>1</sub> and R<sub>2</sub> relaxation rates. The tailored contrast can be created by concurrent labeling of the two contrast agents as well as combining separately labeled cells with the two contrast agents. The proposed method would be applied to generate tailored contrast for efficient detection of magnetically-labeled cells in molecular imaging and cell-based therapy.</p>","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144961530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advances in the Molecular Imaging of Sarcoma: An Emphasis on Metabolic Imaging. 肉瘤分子影像学研究进展:以代谢影像学为重点。
IF 2.5 4区 医学
Molecular Imaging and Biology Pub Date : 2025-08-19 DOI: 10.1007/s11307-025-02045-w
Sriya Jonnakuti, Rizwan Naseer, Sze Jia Ng, Hui Chong Lau, Lori Jia, Melika Mirbod, Cyrus Ayubcha
{"title":"Advances in the Molecular Imaging of Sarcoma: An Emphasis on Metabolic Imaging.","authors":"Sriya Jonnakuti, Rizwan Naseer, Sze Jia Ng, Hui Chong Lau, Lori Jia, Melika Mirbod, Cyrus Ayubcha","doi":"10.1007/s11307-025-02045-w","DOIUrl":"10.1007/s11307-025-02045-w","url":null,"abstract":"<p><strong>Purpose: </strong>Sarcomas, malignancies of mesenchymal origin, present significant diagnostic and therapeutic challenges due to their heterogeneity and low incidence. This review aims to examine the evolving role of fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in the management of soft tissue and musculoskeletal sarcomas. Specifically, it seeks to evaluate 18F-FDG PET/CT's utility in detecting metastatic lesions, differentiating benign from malignant tumors, and assessing treatment responses.</p><p><strong>Procedures: </strong>A comprehensive review of the literature was conducted to analyze advancements in PET imaging for sarcomas. Emphasis was placed on 18F-FDG PET/CT's role in complementing conventional imaging techniques, such as computed tomography (CT) and magnetic resonance imaging (MRI). Key aspects of PET imaging in musculoskeletal and cardiac tumors were examined, including its sensitivity and specificity in identifying metastases and its metabolic characterization of various tumor types.</p><p><strong>Results: </strong>18F-FDG PET/CT has demonstrated high sensitivity and specificity in detecting metastatic sarcoma lesions and grading musculoskeletal tumors, such as osteosarcoma, chondrosarcoma, and Ewing sarcoma. Its ability to provide metabolic insights has enhanced differentiation between benign and malignant tumors, including myxomas, lipomas, angiosarcomas, and leiomyosarcomas. Furthermore, in primary and secondary cardiac tumors, 18F-FDG PET/CT has proven valuable for treatment planning by offering detailed metabolic characterization.</p><p><strong>Conclusions: </strong>18F-FDG PET/CT serves as a critical imaging modality in the diagnosis, staging, and treatment monitoring of sarcomas. By complementing conventional imaging techniques, it enhances the accuracy of tumor characterization and facilitates improved clinical decision-making. Its application in both musculoskeletal and cardiac sarcomas underscores its growing significance in oncologic imaging, making it a valuable tool in optimizing patient outcomes.</p>","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144883166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信